Results For "Jubilant-Ingrevia"

23 News Found

Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr

News | June 05, 2021

Jubilant Pharmova posts Q4FY21 consolidated PAT of Rs. 213.90 Cr

The company is doubling its chemistry research capacity that should commission by Q2'FY22

CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating

News | May 11, 2021

CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating

The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.

Jubilant Pharmova recovers: ICICI Securities

News | February 13, 2021

Jubilant Pharmova recovers: ICICI Securities

Jubilant announced the completion of demerger of pharma and LSI business into two separate companies

Latest Stories

Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub

AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal

Astec LifeSciences posts robust Q3 growth

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging